임상시험용 블록체인 시장 - 예측(2026-2031년)

Blockchain In Clinical Trials Market is projected to expand at a 22.11% CAGR, attaining USD 508.43 million in 2031 from USD 153.392 million in 2025.

The blockchain in clinical trials market represents the application of distributed ledger technology (DLT) to enhance the integrity, security, and efficiency of the clinical research process. This specialized market involves leveraging blockchain's core architectural principles-decentralization, immutability, cryptographic security, and consensus-based validation-to create verifiable, transparent, and tamper-resistant systems for managing clinical trial data and processes. It is not a singular product but rather a foundational technological layer designed to address systemic challenges in multi-stakeholder, highly regulated clinical research environments. The ultimate goal is to improve trust, collaboration, and data quality across the entire trial lifecycle.

Market adoption is driven by the urgent need to address persistent pain points in traditional clinical trial models. A primary catalyst is the demand for unprecedented data integrity and traceability. Blockchain's immutable ledger creates an auditable, time-stamped chain of custody for all trial data-from patient consent forms and case report forms to adverse event reports. This inherent feature directly combats risks of data manipulation, fraud, and unintentional errors, thereby strengthening regulatory submissions and scientific validity. Furthermore, the technology promises to streamline historically cumbersome and siloed data management. By enabling secure, permissioned real-time data sharing among sponsors, contract research organizations (CROs), sites, and regulators on a single, reconciled source of truth, blockchain can reduce reconciliation delays, administrative overhead, and the potential for discrepancies.

A significant value proposition is the enhancement of patient-centricity and trust. Blockchain can empower participants by providing a secure, transparent mechanism for managing their consent and controlling access to their personal health information. Smart contracts-self-executing code on the blockchain-can automate elements of the consent process and even facilitate direct, compliant incentives to participants. This transparency and perceived control have the potential to improve recruitment, retention, and overall engagement by building patient trust in the research ecosystem.

Geographically, North America has been the pioneering and most advanced market, largely due to its mature pharmaceutical R&D sector, high concentration of technology innovators, and a regulatory environment that has shown openness to technological pilots and discussions. The region's strong emphasis on data security (e.g., HIPAA) and its leading role in global drug development have created a fertile ground for initial exploration and proof-of-concept development in this space.

Despite its transformative potential, the market faces substantial barriers to widespread commercial deployment. The primary challenge is the profound complexity of integrating a novel, decentralized architecture into existing, highly complex, and regulated clinical trial workflows and legacy IT systems (EDC, CTMS, etc.). Achieving interoperability without creating new data silos is a significant technical hurdle. Furthermore, the regulatory pathway for blockchain-based systems remains ambiguous. Regulatory agencies like the FDA and EMA require clarity on how data audit trails on a blockchain satisfy existing guidelines (e.g., 21 CFR Part 11, ALCOA+ principles), and who bears ultimate responsibility in a decentralized network. Scalability and performance for handling large-scale trial data, along with concerns over data privacy (e.g., reconciling blockchain's transparency with GDPR's "right to be forgotten"), also present critical adoption constraints.

The competitive landscape is nascent and fragmented, comprising a mix of established enterprise technology providers, specialized blockchain startups, and consortia formed by pharmaceutical companies. Key players compete on the robustness of their underlying blockchain protocol, the development of user-friendly application layers that abstract the technology's complexity, and the ability to form strategic partnerships with industry stakeholders. Success hinges not just on technological prowess, but on deep domain expertise in clinical operations and regulatory affairs, and the ability to demonstrate tangible return on investment through operational efficiencies and risk mitigation.

In conclusion, the blockchain in clinical trials market is at a pivotal stage of exploration and pilot validation rather than mass implementation. Its growth is conceptually supported by the compelling need for greater transparency, efficiency, and trust in a multi-billion-dollar industry burdened by inefficiency. For industry experts, strategic focus must center on moving beyond theoretical use cases to solving practical integration and scalability challenges, actively engaging with regulators to co-create evaluation frameworks, and quantifying the real-world value in terms of reduced cycle times, lower audit costs, and improved data quality. Success will depend on collaborative, consortium-based approaches that align the incentives of all stakeholders and demonstrate that the technology can deliver concrete improvements to the speed and reliability of bringing new therapies to market.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Blockchain in Clinical Trials Market Segmentation

• By Blockchain Type
• Private
• Public
• Consortium
• Hybrid
• By Application
• Patient Data Management
• Clinical Data Exchange & Sharing
• Drug Traceability & Authenticity
• Smart Contracts
• Others
• By End-User
• Pharmaceutical & Biotech Companies
• Research & Academic Institutes
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY BLOCKCHAIN TYPE

• 5.1. Introduction
• 5.2. Private
• 5.3. Public
• 5.4. Consortium
• 5.5. Hybrid

6. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Patient Data Management
• 6.3. Clinical Data Exchange & Sharing
• 6.4. Drug Tracebility & Authenticity
• 6.5. Smart Contracts
• 6.6. Others

7. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Research & Academic Institutes
• 7.4. Others

8. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Italy
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Taiwan
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. IBM
• 10.2. Microsoft Corporation
• 10.3. Oracle Corporation
• 10.4. Accenture PLC
• 10.5. Consensys Health
• 10.6. Bitfury Group Limited
• 10.7. FarmaTrust
• 10.8. LabTrace
• 10.9. Chronicled
• 10.10. iSolve

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations